P95 Expands its Global Presence with a New USA Office
P95 Expands Its Global Presence with a New USA Office
P95, a leading global provider of clinical and epidemiology services focused on vaccines and infectious diseases, has opened its first office in the USA. Based in the Research Triangle Park in North Carolina, the largest research park in the USA, this expansion underlines P95s commitment to delivering high-quality research solutions to our clients and partners across the globe.
The North Carolina USA office joins P95’s regional hubs in Europe, Africa, Southeast Asia and Latin America with over 200 experts in clinical operations, epidemiology, pharmacovigilance, data management, and biostatistics working together across continents and time zones. Together they will continue to provide first-class customized solutions covering clinical studies phase I-IV, epidemiology and RWE, and scientific and clinical development consulting.
"This is a significant milestone in our growth and development as a global contract research organization. This expansion will allow us to better serve our clients and partners in the region, as well as to leverage the opportunities and resources that North Carolina offers as a leading biotech and pharma hub. We look forward to building long-term relationships and delivering excellence in research in the USA and beyond." – Thomas Verstraeten, P95 Chief Executive Officer
P95 is proud to be a truly global CRO, with the ability to offer high-quality services tailored to the local needs and regulations of each country where it operates. P95’s commitment to excellence in research is driven by its passion for vaccines and infectious diseases and its dedication to advancing public health worldwide.
More about P95's full services
P95’s Journey From Epidemiology Consulting to Comprehensive CRO
P95's Journey From Epidemiology Consulting to Comprehensive CRO
In a recent interview for Ampersand Capital Partners, our CEO, Thomas Verstraeten, and Chairman, Benoit Bouche shared pivotal insights into P95's growth from an epidemiology consulting into a global comprehensive Contract Research Organization (CRO).
Almost one year from P95's partnership with Ampersand Capital Partners, the article dives deeper into P95’s expanding global reach, client-focused capabilities, and commitment to global health that bring our company to the forefront.
"In addition to COVID, there is an astounding need for vaccines to treat infectious diseases on a global scale, such as RSV, influenza, HMPV, and fast-spreading Dengue in and around South America. The demand has no limit, and P95 is ready to rise to the challenge and meet this need." - Thomas Verstaeten, P95 CEO
“Large-scale CROs often lack the necessary specialization and agility required to support the intense demand for clinical vaccine development. P95, with its reputation for deep expertise and flexibility in providing customized client services, stands out in this landscape." – Benoit Bouche, P95 Chairman
About Ampersand Capital Partners
Founded in 1988, Ampersand is a middle market private equity firm with more than $3 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm’s core healthcare sectors.
P95 welcomes John O’Brien as Chief Business Officer
P95 welcomes John O’Brien as Chief Business Officer
We are excited to welcome John O’Brien as our new Chief Business Officer! John has a proven track record of driving commercial success and building strategic partnerships, bringing a wealth of experience to our team.
"I am delighted to welcome John to our team! His visionary leadership and innovative approach will be instrumental in driving our company forward as we continue our jounrey to be the premier provider of clinical and epidemiological services for vaccine developers worldwide." - Thomas Verstraeten, P95 Chief Executive Officer
John joins us from his previous role as Chief Commercial Officer at Excelya Group, a contract research organization (CRO) providing full-service clinical, FSP, and resourcing solutions. Prior to this, John held leadership and business development roles in various clinical CROs including Cmed, Chiltern, Theorem Clinical and Parexel.
Please join us in extending a warm welcome to John! We are excited to have him on board and look forward to his valuable contributions to our organization's continued success.
Stay tuned for exciting updates as we embark on this new chapter together!